MissionIRNewsBreaks – Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Announces IPO Closing

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a producer, developer and operator of popular augmented reality interactive entertainment games and toys in China, today announced the July 30, 2019 closing of its underwritten initial public offering (“IPO”). According to the update, the IPO consisted of 2,000,000 ordinary shares priced at $4 each, before underwriting discounts and commissions, and resulted in gross proceeds of $8,000,000 before underwriting discounts and commissions and offering expenses. Blue Hat raised the proposed deal size from 1,800,000 as reflected in the original registration statement through filing an additional statement to accommodate the upsizing. Blue Hat offered all of the ordinary shares, and the offering was conducted on a firm commitment basis.

To view the full press release, visit http://ibn.fm/72TOm

About Blue Hat Interactive Entertainment Technology

Blue Hat, headquartered in Xiamen, China, is a producer, developer and operator of augmented reality interactive entertainment games and toys, including interactive educational materials, mobile games, and toys with mobile game features. For more information, visit the company’s website at www.BlueHatGroup.net.

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Initiates First Phase of Branding Lead Drug Candidate

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced it has initiated the first phase of branding its lead drug candidate, Oncoprex(TM) immunogene therapy, and has completed and submitted non-proprietary drug name selections to the American Medical Association’s United States Adopted Names (“USAN”) Council. According to the update, Genprex will, upon receipt of USAN feedback expected later this year, submit its non-proprietary drug name selections to the World Health Organization for International Nonproprietary Names (“INN”) status. By mid-2020, the company expects to obtain an approved non-proprietary drug name. “Developing and obtaining regulatory approval of a non-proprietary drug name is a requirement for bringing our lead drug candidate to market,” Genprex Chairman and CEO Rodney Varner said in the news release. “We’re one step closer to achieving this regulatory milestone. An approved non-proprietary drug name will also make our lead drug candidate more widely recognizable to clinicians and physicians and most importantly, to patients living with non-small cell lung cancer.”

To view the full press release, visit http://ibn.fm/8p8qJ

About Genprex Inc.

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Pressure BioSciences Inc.’s (PBIO) Entry into CBD Market Aims Next-Gen Nanoemulsification Platform at Critical Water-Solubility Issues

• PBIO’s proprietary Ultra Shear Technology (UST) platform achieves the long sought-after ability to create truly water-soluble CBD oil that can provide optimized bioavailability
• CBD sales are projected to reach $89 billion by 2024 with a CAGR of 37 percent (2018-2024 forecast period)
• Analysts predict that the biggest short-term challenge for CBD businesses will be oversaturation and stiff competition in the marketplace; companies producing the highest-quality, most bioavailable CBD products are expected to earn top customer loyalty

Finding success in the lucrative yet ultra-competitive CBD industry is a daunting challenge for businesses in the space, with oversaturation in the marketplace being a real concern. The cannabis market was valued at $14.5 billion in 2018 and is projected to reach $89.1 billion by 2024, with a compound annual growth rate of 37 percent during the forecast period, according to Mordor Intelligence (http://ibn.fm/fCnCI). CBD manufacturers may find tapping into this booming trend to be short-lived if their CBD offerings don’t stand up to consumers’ expectations that the products they purchase are as beneficial as advertised.

Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of high pressure-based instruments, consumables and related services for the global life sciences and other industries, has developed a novel, proprietary process that has wide potential in the cannabis sector by solving one of the most critical problems facing CBD manufacturers today: the extremely poor water solubility of CBD oil. The recent launch of PBIO’s BaroShear K45 system, based on the company’s proprietary Ultra Shear Technology (UST) platform, has been optimized for the unique purpose of creating high quality, water-soluble nanoemulsions of CBD oil in water, as a news release details (http://ibn.fm/MY4mE).

CBD, a non-psychoactive compound believed to offer powerful health benefits, is extracted from the cannabis plant in an oil. After ingestion, because oils are not well absorbed, most of the CBD is flushed from the body, leaving little of the product to provide its beneficial properties. Because of these solubility issues, many CBD products on the market today contain an inefficient over-abundance of CBD and/or undesirable chemicals to try and improve solubility and bioavailability.

Dr. Nathan Lawrence, senior advisor to Pressure BioSciences, said that PBIO solves the water-solubility problem of CBD with its patented UST platform, which uses ultra-high pressure to create extreme shearing forces to make highly stable, homogenized nanoemulsions of materials that normally do not mix, such as CBD oil and water.

“The unique concept of the BaroShear K45 system is based on PBIO’s proprietary UST platform. It was designed for the efficient and affordable manufacture of limited quantity oil-based material into high quality, water-soluble nanoemulsions,” Dr. Lawrence stated in a news release. “The BaroShear K45 system uses a custom-designed, highly responsive ultra-high pressure generating subsystem, matched to our patented BaroIsolator device and NanoGap valve. This allows for the highest effectiveness possible at working pressures up to 45,000 psi. The BaroShear K45 system is ideally suited for processing small amounts (e.g., 50 mL – 2 L) of high value product, such as CBD oil, into water-soluble nanoemulsions with high yield.”

In a critical review report on cannabidiol (CBD), the World Health Organization’s Expert Committee on Drug Dependence noted that, while CBD is seen as a useful treatment for a number of medical conditions, there are efficacy issues because of its “poor aqueous solubility.”

“The absorption of CBD from the gastrointestinal tract is erratic, and the resulting pharmacokinetic profile is variable. Bioavailability from oral delivery was estimated to be 6 percent due to significant first-pass metabolism,” the report states (http://ibn.fm/k9TiL).

For most oil-based products, the ability to prepare them as nanoemulsions can improve the product’s absorption, medicinal benefits, visual appearance and sensory presentation. The biggest challenge in the short-term for CBD businesses will be oversaturation and stiff competition, a Forbes article notes (http://ibn.fm/rq67C). As consumers start to learn more about CBD and approach products with more discerning tastes, companies will need to start differentiating themselves from their competitors through smart branding and the delivery of excellent products.

Two short videos released by PBIO (http://ibn.fm/T4eUX and http://ibn.fm/ENM6e), showing how its patented UST platform was able to process CBD plant oil into a water-soluble nanoemulsion, give a quick lesson in PBIO’s proprietary technology. When the UST-processed CBD oil was added to different liquids – such as a soft drink, a sports drink and a beer – the nanoemulsified CBD oil completely dissolved in each liquid. For CBD companies seeking a way to stand out from the rising hordes of competition, PBIO’s BaroShear K45 system could be a true game changer.

“We are looking forward to working with the early adopters of this exciting technology platform,” Richard T. Schumacher, president and CEO of PBIO, said in a news release. “Early adopters will be the first to use the UST platform in the CBD field, thus giving them a significant head-start over companies who choose to wait or use other methods.”

For more information, visit the company’s website at www.PressureBioSciences.com

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Summarizes DehydraTECH(TM) Technology Licensees

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today reported on its existing technology licensees that have entered definitive contracts to use its revolutionary DehydraTECH(TM) absorption technology within their existing and emerging brands. “The first half of 2019 delivered a period of unprecedented achievements for Lexaria. We signed more license agreements than ever before in our Company’s history, many of which were larger in scope than anything previous,” Lexaria Chief Executive Officer Chris Bunka said in the news release. “We also launched our brand-new business division Lexaria Nicotine which is disrupting nicotine delivery methods that already attracted one of the world’s largest nicotine companies, which has licensed our technology.”

To view the full press releases, visit http://ibn.fm/CHTEH

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. licenses disruptive, patented-delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates, more rapid delivery to the bloodstream, and important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) Posts Updated Terms to Spring Oaks Acquisition

Green Growth Brands (CSE: GGB) (OTCQB: GGBXF), a lifestyle-oriented cannabis company, on Monday announced an amendment to the share purchase agreement dated June 3, 2019 with Spring Oaks Greenhouses, Inc. Per the amended agreement, GGBXF will acquire all of the issued and outstanding shares of capital stock of Spring Oaks. According to the amendment, the purchase price of $54,650,000 will be comprised of a previously paid deposit of $1,350,000; a cash payment of $2,000,000 at closing, subject to certain adjustments acknowledged in the agreement; a cash payment of $3,000,000 due on August 31, 2019; the issuance of 7,133,297 common shares of GGBXF to the owners of Spring Oaks representing a total of $17,100,000 at a price of $2.39 each; the issuance of 8,094,210 additional common shares to the owners of Spring Oaks representing a total of $14,000,000, at a price of $1.72 each; the issuance of a two-year convertible secured promissory note in the aggregate principal amount of $11,400,000 that will bear interest at a rate of 15%, payable after the first year, and with a 24 month maturity date from closing and a conversion rate equal to $2.39; and the issuance of a one-year convertible secured promissory note in the aggregate principal amount of $5,800,000. The one-year note will bear interest at a rate of 15%, simple interest, per annum, and has a maturity date of 12 months following the date of closing. At the option of Spring Oaks, the one-year note is convertible on the maturity date into common shares of GGBXF at a conversion rate of $1.72. The shares issued as part of the purchase price are subject to a lock-up agreement for 20 months following the date of closing, to be released in increments of 1/20 over that time period. In addition, GGBXF will pay a fee of $500,000 to Jeremy Giles in connection with the anticipated closing. The fee will be comprised of a cash payment in the amount of $250,000 and the issuance of common shares totaling $250,000, priced at $1.72 each. GGBXF and Giles are expected to enter into a consulting services agreement for governmental relations services.

To view the full press release, visit http://ibn.fm/YiVJW

About Green Growth Brands

Green Growth Brands creates remarkable experiences in cannabis and CBD. Led by CEO Peter Horvath and a leadership team of consumer-focused retail experts, the company’s brands include CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, and Meri + Jayne. The company also has a licensing agreement with the Greg Norman(TM) Brand to develop a line of CBD-infused personal care products designed for active wellness. Already driving the strongest sales per square feet in the cannabis industry, GGB is expanding its cannabis operations throughout the U.S., its CBD presence at ShopSeventhSense.com, in malls across the country and at DSW shoe stores—and that’s just the beginning. For more information, visit the company’s website at www.GreenGrowthBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to GGBXF are available in the company’s newsroom at http://ibn.fm/GGBXF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) Increases Licensed Production Capacity

Organigram Holdings (TSX.V: OGI) (NASDAQ: OGI), parent company of Organigram Inc., a leading licensed producer of cannabis, recently obtained approval from Health Canada for the licensing of all of the company’s Phase 4A buildout plans, increasing its total licensed production capacity to 61,000 kg. per year (http://ibn.fm/jGAdq). An article discussing the company reads, “Once fully licensed and operational, the full Phase 4 expansion is expected to bring the company’s annualized target production capacity to approximately 113,000 kg. of dried-flower equivalents. . . . ‘Organigram’s continued expansion reflects ongoing growth in the cannabis marketplace, including increasing demand as new retail stores come online in Alberta, Ontario, Quebec and British Columbia,’ CEO Greg Engel said in a news release. ‘The expansion of our facility and production capacity will help ensure we have additional product for extraction for the launch of the edibles and derivatives market before the end of 2019.’”

To view the full article, visit http://ibn.fm/hg8qa

About Organigram Holdings Inc.

Organigram Holdings is a TSX Venture Exchange- and NASDAQ Global Select-listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada. Organigram is focused on producing the highest-quality, indoor-grown cannabis for patients and adult-recreational consumers in Canada, as well as developing international business partnerships to extend the company’s global footprint. Organigram has also developed a portfolio of legal adult-use recreational cannabis brands including the Edison Cannabis Company, Ankr Organics, Trailer Park Buds and Trailblazer. Organigram’s primary facility is located in Moncton, New Brunswick, and the company is regulated by the Cannabis Act and the Cannabis Regulations (Canada). For more information, visit the company’s website at www.Organigram.ca.

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://ibn.fm/OGRMF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Research Highlights Virtues of INmune Bio Inc.’s (NASDAQ: INMB) Strategy in Fighting Cancer with Body’s Own Natural Cells

• California-based INmune Bio is developing therapies to battle cancers and Alzheimer’s disease by more effectively engaging the body’s own natural defenses
• Research published in a peer-reviewed scientific journal shows a mechanism by which scientists can track and strategize natural killer cell promotion as an innate physical response to cancer in lieu of other pharmaceutical inducements
• INmune Bio’s INKmune product, derived from the cell line used in its research, naturally targets “residual disease” cells that may survive other cancer treatments and revitalize themselves to create a relapse of cancer

The battle to marshal naturally occurring cells within the human body to destroy cancerous tumors has gained new intelligence that appears to strengthen an immunotherapy strategy employed by clinical-stage biotechnology company INmune Bio Inc. (NASDAQ: INMB). The encouraging report arises from research on tumor-primed vs. cytokine-primed human natural killer (NK) cells, published in June in peer-reviewed, open-access scientific journal PLOS ONE (http://ibn.fm/HuKXg).

“We are delighted to be sharing these data describing the unique molecular pathways triggered within human NK cells upon priming with INmune Bio’s own INB16 (INKmune) cell line,” INmune Bio co-founder and Chief Scientific Officer Dr. Mark Lowdell, who co-authored the study, stated in a news release announcing the publication (http://ibn.fm/LYvqj). “This work has combined expertise across many groups, and it was important to publish these data in a highly-regarded open access journal to ensure that they are available to the widest possible audience.”

INmune Bio is a clinical stage immuno-oncology company focused on successfully harnessing patients’ immune systems to treat cancer by targeting cells that may survive initial therapies and become resurgent to cause a relapse of the cancer. By controlling these “residual disease” cells, INmune Bio hopes to enable patients to live longer through a novel mechanism of action and a precision medicine approach that suppress or eliminate relapses.

The company’s INKmune drug is a biologic therapy that strives to activate the body’s innate immune system by “priming” NK cells that are at rest to go on alert, seek out and destroy cancerous cells. The therapy uses simple IV infusion of the INKmune cell line – a tumor cell product – to call up the NKs for duty.

The PLOS ONE report notes that the research comparing tumor cell activation to the results from increasingly popular work on cytokine-mediated activation (http://ibn.fm/A9UXg) shows that the two therapies demonstrate distinct effects and that tumor therapy has the potential to be more effective against cancer targets with potentially fewer side effects than the administration of cytokines such as IL-2 or IL-15.

The research paper identifies a unique signaling “fingerprint” expressed by NK cells after binding to CTV-1 tumor cells, which are the parent clones of INmune Bio’s INB16 cells. Scientists are then able to use data obtained from the “fingerprint” to build strategies for immunotherapy treatments.

Lowdell went on to state, “These data confirm that the primed NK cells generated by INB16 stimulation upregulate genes, which are crucial to NK-mediated killing of patients’ cancer cells, such as CD70 and CXCL10. These differences in gene expression may explain the greater cytotoxic activity of INB16 primed NK cells in vitro compared to cytokine primed cells which may lead to greater clinical efficacy.”

INmune Bio is also completing testing of its INB03 product, a checkpoint inhibitor that targets myeloid-derived suppressor cells (“MDSC”) that may produce a “shield” preventing a patient’s immune system from attacking cancer cells. The company is also exploring Alzheimer’s disease therapies using its XPro1595 product that targets the microglial immune cells of the brain, which may cause neuroinflammation that can kill nerve cells and promote synaptic dysfunction in the brain.

For more information, visit the company’s website at www.INmuneBio.com

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Upholds Commitment to Quality amid CBD Shortage

The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF), a cannabis-focused research and development company, remains dedicated to maintaining its high standards in the midst of a growing cannabis supply gap. An article discussing the company reads, “TGOD is one of three organic cannabis growers in Canada. No synthetic pesticides or fertilizers are used in the company’s growing process. The company is also dedicated to creating a smaller environmental footprint by using less water and energy, low-cost power solutions and smarter efficient packaging. By growing organically and at low costs, TGOD’s final product demands a premium in the market, thereby increasing margins. . . . In April, Marijuana Business Daily reported that Canadian cannabis wholesalers are reporting a CBD shortage (http://ibn.fm/CaGzx). The demand for product has been higher than expected, and companies such as TGOD are working to ensure that the gap is filled, without sacrificing on quality standards. Certified organic by North America’s most-recognized organic certification bodies — Pro-Cert and ECOCERT Canada — TGOD stands by the slower, more sustainable methods of growing, believing them to be the best way to provide consumers with the premium products they deserve.”

To view the full article, visit http://ibn.fm/93jZt

About the Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman Holdings is a publicly traded, premium, global, organic-cannabis company with operations focused on medical-cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic-hemp, CBD-oil operations in Canada and, through its wholly owned subsidiary HemPoland, distributes premium-hemp CBD oil in the European Union. The company grows high-quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe, consistent product. TGOD has a planned capacity of 219,000 kgs. and is building 1,643,600 square feet of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. For more information, visit the company’s website at www.TGOD.ca.

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) is “One to Watch”

• China’s AR industry is estimated at RMB$55 billion in 2020
• Favorable Chinese government policies emphasize research and development of new technologies such as AR
• Few direct competitors in China create exceptional potential for AR application in educational materials and smart toys
• Total retail sales of toys and games in China soared to RMB$276.5 billion in 2017 with an annual growth rate of 19.9%
• Shift toward intelligent and interactive toys and games, along with rising disposable income in China, helped retail sales of electronic toys grow 24% while traditional toys grew at 7% in 2017
• Extensive portfolio of IR property with strong research and development teams and partnerships

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) is a cutting-edge creator, developer and operator of popular augmented reality (“AR”) interactive smart toys and educational games in China. Blue Hat’s mobile-connected entertainment platform connects physical items to mobile devices through wireless technologies, creating a unique interactive user experience in various mobile games, interactive educational materials and toys with mobile game features.

Blue Hat designs original toys and games that utilize augmented reality technology, motion capture technology, image recognition technology, voice control, light sense technology, infrared, levitation induction, and other trending scientific technologies to transverse the virtual with reality. Blue Hat creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. This combination provides users with a more natural form of human computer interaction, enhances a user’s perception of reality, and delivers a more immersive entertainment experience.

Proprietary Technology

Founded in 2010, Blue Hat’s proprietary technology, product research and development, marketing channels and brand operation are the cornerstones of the business. Blue Hat focuses on the combination of “online” and “offline” activity and the interaction between “entertainment” and “product” to create a high-tech entertainment platform combining mobile games and AR. With the help of computer graphics, motion capture technology, image recognition technology and visualization technologies, Blue Hat accurately “places” virtual objects into the physical world, creating a new and stimulating visual environment for users.

Blue Hat recently displayed a variety of its sci-tech products at the Guangzhou International Toy Exhibition in China including AR Racer, Elastic Bubbles, AR Space Track, AR Alloy Toy Car, AR Need a Spanking, 5D Animated Magic Aquarium, Bug Travelers, AR Picture Book and other interactive games and smart toys.

The company has multiple products in development including new generations of four primary product lines and two new product lines.

Patents and Copyrights

Blue Hat’s advanced AR technology in interactive entertainment is protected by 178 authorized patents with 44 patents in various stages of the application process.

Another 14 applications for Patent Cooperation Treaty, or PCT, have been filed for international patents. As of March 31, 2019, the company owns 645 copyrights for artwork, 71 registered trademarks and 27 software copyrights.

Sales and Marketing

There has been rapid growth in the toys and games industry in China over the last several years. Total retail sales of toys and games in China soared from RMB 111.8 billion in 2012 to RMB 276.5 billion in 2017 with an average annual growth rate of 19.9% in 2017. Blue Hat believes the company is well positioned with little competition as the toy industry rapidly shifts toward intelligent and interactive toys and games. Retail sales of electronic toys grew at 24% annually in 2017 while that of traditional toys grew at 7%.

In addition to a powerful ecommerce presence, Blue Hat has long-term relationships with partnered distributors that place the company’s AR interactive entertainment products into well-known international retail chains and retail outlets. Blue Hat’s integrated online and offline sales channels include e-commerce giants such as Amazon and Alibaba, retail chain stores and the company’s physical experience store located in Xiamen, China. Blue Hat plans to open or franchise approximately 100 additional stores in China by 2021.

Blue Hat’s community-based platform offers users a highly engaged and interactive community with online communication forums and offline social activities. The company advocates a new model of “teaching through lively activities” and combines AR technology with education, integrating its products into situational teaching, roleplaying and man-machine interaction. This novel educational experience helps realize optimal transformation of information, creating a knowledge and enhancing cognition.

Management

Director and CEO Xiaodong (Sean) Chen has over 20 years of experience creating, developing and producing toys and games related products. Chen earned his EMBA from Renmin University of China and has been chairman of the board of directors and general manager of Fujian Blue Hat Interactive Entertainment Technology Ltd. since August 2015.

CFO and Director Caifan, who has over 20 years of financial accounting and taxation experience, earned a degree in finance from Hunan University of Finance and Economics. He has served as director, deputy general manager and financial controller of Fujian Blue Hat Interactive Entertainment Technology Ltd. since August 2015.

Jianyong Cai, chief technology officer and director, has over 35 years of experience in data communication principles, communication network foundation, software engineering, communication network theory and technology and computer network architecture. He holds degrees in data communication principles, communication network foundation and software engineering from University of Science and Technology of China. He has been director, deputy general manager and chief engineer of Fujian Blue Hat Interactive Entertainment Technology Ltd. since January 2010.

For more information, visit the company’s website at www.BlueHatGroup.net

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) Announces Proprietary Nano-Emulsion Technology for Rapid-Onset of Cannabinoid Effects

• Organigram’s proprietary nano-emulsion technology is expected to provide an initial onset of effects within 10 to 15 minutes for cannabis beverages
• The company’s shelf-stable, thermally stable, water-compatible and palatable cannabinoid nano-emulsion formulation allows for the production of both liquid and powdered beverage products
• Organigram plans to launch dried powder formulation beverage products in early 2020

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI), the parent company of leading licensed cannabis producer and cannabis-derived products manufacturer Organigram Inc., has developed a proprietary nano-emulsification technology. This new unique, fast-acting formulation will allow for the production of both powdered and liquid cannabinoid products. The development comes in the context of the much-anticipated legalization of adult recreational-use cannabis edibles in Canada and the ensuing boost in demand, as the company noted in a news release (http://ibn.fm/zy5Pt).

Organigram focuses on high-quality, indoor-grown cannabis for both medical patients and adult recreational users. Its proprietary technology allows for the development of products with a quick onset of the cannabinoid effect within 10 to 15 minutes. To determine the onset of the products, Organigram studied cannabinoid particles at a size of 20 nanometers. Organigram’s nano-emulsion technology is stable to temperature variations, mechanical disturbance, salinity, pH and sweeteners. Further testing is anticipated to occur in order to confirm the onset of action and the duration of the effect.

Previously, Organigram announced the launch of premium cannabinoid-infused chocolates. The company will also be working toward the release of additional dried powder formulation beverages in Canada in early 2020.

“This is an exciting time for cannabis product makers”, Organigram CEO Greg Engel said in a news release. “To ensure the satisfaction of adult consumers, companies have to deliver both predictability and reliability. Organigram’s technology and the powdered formulation put the customer in control, allowing them to infuse just about any beverage… This new method of delivery allows for a completely new experience.”

At the same time, Organigram is also actively seeking a partner with proven experience within the beverage market to take advantage of the liquid formulation it has developed.

On July 10, Organigram announced a collaboration with Lift & Co. Corp. (TSX.V: LIFT) (OTCQB: LFCOF), supporting the launch of Canada’s first branded cannabis educational program (http://ibn.fm/KEQiK).

The program, developed in partnership with MADD Canada, aims to promote the responsible sale of cannabis and will be available via the Lift & Co. CannSell retail training program. Currently, CannSell is the only mandatory, provincially approved cannabis training program for all Ontario retail workers. Organigram is the first licensed cannabis producer in Canada to partner up with Lift & Co. for the purpose of educational content creation.

The rollout of the branded Organigram module of the program started in June 2019. The module will deliver digital training on Organigram’s three-tiered growing methodology, as well as best practices.

“This module will allow Organigram to connect directly with budtenders at any time and educate retail staff about their product attributes, best practices and stay top-of-mind with budtenders – the only people in the value chain speaking directly with consumers,” Lift & Co CEO Matei Olaru added.

For more information, visit the company’s website at www.Organigram.ca

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://ibn.fm/OGRMF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html